UNITY Biotechnology Inc (UBX) オプション

UBX, new 52 week low

UBX under $2

Don’t get fooled by this company either …. Below $1 for 30 days they will do same as WISA


UBX (Unity Biotechnology, Inc.) has performed two reverse stock splits. The first occurred on January 18, 2018, at a ratio of 1-for-4. The second reverse split was on March 23, 2020, at a ratio of 1-for-8.

I was into this one quite some time ago. They have been stuck in a rut and have been paying employees in stocks for quite some time. They need something major to bail them out.

UBX under $2

UBX under $2

I was lucky a few years ago and then it crashed and never recouped. I am now in IOVA. Flipped it twice already and just bought back in.

This was on my watchlist so I must have played it at some point. Glanced at it today and thought it might be good for a swing but passed on it. It needs something to go in their favor to get some momentum.

This company looked promising but then they got stagnant. Plus they keep, issuing shares to pay employees,

Thought about UBX here, 1.45 - 1.47, couldn't push the button. Looks like a duck, smells like a duck...


Maybe around the $? Either way, i'll miss out.

I give up. IOVA for me. Just flipped for,$40,000 on a pop.

This company is dead and has been for over a year now. All they do is keep issuing shares to pay their employees.

UBX under $2

Glad I dumped this one and got into IOVA!

Ther meme stock..good news

https://www.prnewswire.com/news-releases/theralink-acquires-exclusive-landmark-immunotherapy-patent-including-biomarker-from-vanderbilt-university-301787847.html

Wedge forming

I also did, but now I am and have been just watching.

Made money UBX$..now back on the watch list, gl...

Until they have a success, temporary moves up then insiders dumping for their pay.

Starting to climb back up.

Not anymore.

Chief Medical Officer leaving, trial was a bust. Does anyone have hopesin this one making a comeback?

Unity Biotechnology Shares Plumb New Depths After Study Setback >UBX
11:44 am ET March 27, 2023 (Dow Jones) Print

By Colin Kellaher

Shares of Unity Biotechnology Inc. lost more than half of their value and hit an all-time low Monday after the biotechnology company's lead pipeline candidate UBX1325 missed a key goal in a Phase 2 study in wet age-related macular degeneration, or wet AMD.

Unity said UBX1325 failed to achieve non-inferiority versus aflibercept at 24 weeks on the best corrected visual acuity test.

In a research note, Mizuho analysts Salim Syed and Erik Lavington said they cut their price target on Unity shares to $6 from $12 after removing wet AMD, saying they don't see a likely viable go-forward for UBX1325 in the indication.

Mizuho also lowered its probability-of-success forecast for UBX1325 in diabetic macular edema to 25% from 33%.

Unity said it plans to assess and optimize its resource allocation for future development of UBX1325 after it fully analyzes the study results.

The Mizuho analysts said Unity's $75 million of net cash is worth roughly $5 of their $6 price target, and they noted that the market may not want full credit for the cash due to continued spending by the South San Francisco, Calif., company.

Unity shares were recently changing hands at $2.00, down nearly 52% and reaching their lowest level since the company went public in May 2018.

Trial was positive, up goes the stock imo ...

Bad for investors.

Better for bottom line to pay employees w/shares ...

This has got to be the ugliest chart ever, I’m gonna grab some. Lol

Amazon revenue for the twelve months ending December 31, 2022 was $513.983B

SMH

Right but Amazon does that too, soooo ??, had bad trial result, gl...

How can one make any money when there is constant dilution as the company pays its employees in shares?

..time to reload, $3.80's.. UBX$ money maker ...

https://ih.advfn.com/stock-market/NASDAQ/unity-biotechnology-UBX/stock-news/90195384/amended-statement-of-ownership-sc-13g-a

UNITY Biotechnology to Host Investor Call to Review Data from the UBX1325 Program and Provide an Overview of the ENVISION Wet AMD Study
8:00 am ET February 9, 2023 (Globe Newswire)

-Investor call with retinal expert Robert B. Bhisitkul, M.D., Ph.D., to be held on Tuesday, February 14, 2023 at 7:00 a.m. PT/ 10:00 a.m. ET-

-Complete 16- and 24-week safety and efficacy data from phase 2 ENVISION study in wet AMD expected in Q1 2023-

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host an investor call to discuss lead program, UBX1325, as a potential treatment solution to address the unmet medical need present in age-related diseases of the eye on Tuesday, February 14, 2023 at 7:00 a.m. PT/ 10:00 a.m. ET. Robert B. Bhisitkul, M.D., Ph.D., of University of California San Francisco School of Medicine will review data from the Phase 2 BEHOLD study in diabetic macular edema, followed by an update on upcoming data readouts from the Phase 2 ENVISION study in patients with wet age-related macular degeneration. The Company expects to have 16- and 24-week safety and efficacy data from the ENVISION study in the first quarter of 2023.

A live question and answer session will follow the formal presentation. The webcast can be accessed in the "Investors and Media" section of our website, www.unitybiotechnology.com, under "Events & Presentations" or by clicking here. A replay will be available two hours after the completion of the call and can be accessed in the "Investors & Media" section of our website, under "Events and Presentations."

About UNITY

UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.

I see the form 4's, but to me insiders sell the free shares and make free money I get that, but when can I know it's aggregious?, How can I find out they don't get a salary but instead get paid in shares?..

Appreciate any help or advice.

Thanks

Employees are getting paid with free trading shares. In investors have to be careful and aware as the PPS can suddenly drop.

Employees are getting paid with free trading shares. In investors have to be careful and aware as the PPS can suddenly drop.

Q., what is your go to for insider trading info, form 4, bal sheet 10q?, scheduled trades, maybe all of the above, because honest and surely intentionally it's hard for the homegamer to do the calculations, how many shares and when etc.

Thanks for any thoughts, seems important to learn more about these days..

doubled down today.. UBX$ ...

GLTY.

Bought back $4, running up imo.. UBX$...

Sold for helpful profit today, monitoring.. UBX$...

Moving up I see.

..keep going lol.. UBX$ ...

Not doing well.

Let's gooo !!!!!!! ... $4 c'mon.. ubx$$...

...mad money pick here, gl.. UBX$...

They are paying employees with shares.

Seems they chew up whatever you put down..patient, UBX$...

Can't go down forever, split wiped out now.. UBX$...

I nailed it once. Watching for now. The biggest problem is they are paying employees with shares.